Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

After decades of research, the U.S. Food and Drug Administration (FDA) has approved a test that can detect the buildup of amyloid plaques in the brain—a key marker of Alzheimer’s disease, ...

The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test is an accurate, minimally invasive, accessible measurement of pTau 217 and β-Amyloid 1-42 concentrations in plasma as a proxy for the ...

In patients showing cognitive decline, a new blood test for Alzheimer's is expected to make diagnosis more convenient, accessible and inexpensive than other existing tests.

David Hyde Pierce hosted the CaringKind Gala for Alzheimer's awareness in New York City, sharing his personal connection to the disease that affected both his father and grandfather.

This initiative follows the landmark FDA clearance of the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test developed by Fujirebio Diagnostics in May 2025.

Fujirebio Diagnostics' Lumipulse G β-Amyloid Ratio (1-42/1-40) test has been cleared for use in adult patients aged 55 years and older who have cognitive impairment and are being evaluated for ...

The FDA has approved the first blood test for Alzheimer's disease based on a blood test – from Fujirebio – in a step forward for early diagnosis. The test, dubbed the Lumipulse G pTau217/ß ...

Lumipulse G is not the only Alzheimer’s blood test available, but it’s the first to be introduced since the FDA increased oversight on lab tests. FDA approved Lumipulse G only for patients ...